- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Ibrutinib Data Published in The New England Journal of Medicine Show 68 Percent Overall Response Rate in Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)
A second study in relapsed/refractory chronic lymphocytic leukemia (CLL) also published in the online edition
Ibrutinib Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Data Published in The New England Journal of Medicine
A second study in relapsed/refractory mantle cell lymphoma (MCL) also published in the online edition
Latest Data for Type 2 Diabetes Treatment INVOKANA™ (canagliflozin) to be Presented at American Diabetes Association Annual Meeting
Late-Breaking Phase 3 Results and Health Economics Data are Among 17 Accepted Presentations
STELARA® Phase 3 Study Published In The Lancet Reports One Year Efficacy And Safety In Treatment Of Active Psoriatic Arthritis
Data Show Interleukin-12/23 Inhibitor STELARA Improved Joint, Soft Tissue and Skin Components of Psoriatic Arthritis
Five-Year SIMPONI Data Reported In Treatment Of Signs And Symptoms Of Moderately To Severely Active Rheumatoid Arthritis
Data from Three Pivotal Phase 3 Trials Presented at 2013 EULAR Annual Congres
Janssen, Johnson & Johnson Innovation, Announce Collaboration With Belgian Scientists To Pursue New Research In Neurodegenerative Diseases
Effort Advances Company’s Global Healthy Minds Initiative